FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Minn. Stat. §151.19, subd. 1 bars operating a pharmacy without a Board of Pharmacy license. The Board must require a separate license 'for each pharmacy located outside of the state at which any portion of the dispensing process occurs for drugs dispensed to residents of this state.' Out-of-state applicants must: prove home-state licensure; agree to follow federal law and, when dispensing to Minnesota residents, Minnesota law and rules; disclose officers and dispensing pharmacists; keep Minnesota records retrievable; and offer toll-free pharmacist access at least 6 days and 40 hours per week, with the number on labels. The Board may require its own inspection at the applicant's cost unless the applicant provides a home-state inspection report from the prior 24 months. Pharmacies must be licensed in the categories they practice, including sterile or nonsterile compounding (Minn. R. 6800.0350).

The statute text is the 2025 edition. The Board's website (mn.gov/boards/pharmacy) blocked automated access, so application-form details (e.g., whether a Minnesota-licensed pharmacist is required) were not confirmed; the statute does not require one.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Minn. Stat. §151.01, subd. 35 defines compounding as preparing a drug 'for an identified individual patient as a result of a practitioner's prescription drug order.' It adds that 'All compounding, regardless of the type of product, must be done pursuant to a prescription drug order unless otherwise permitted in this chapter or by the rules of the board.' Anticipatory compounding is limited to the pharmacy's short-term need for filling prescription orders and 'is not the preparation of a compounded drug product for wholesale distribution' (subd. 36). The only statutory non-patient-specific exception is emergency veterinary compounding (§151.253, subd. 4); no Board rule in Minn. R. ch. 6800 authorizes human office-use stock. Nonresident licensees must follow Minnesota law when dispensing to Minnesota residents (§151.19, subd. 1(c)), so the same limit applies to shipments into the state. Office stock must come from a Minnesota-licensed outsourcing facility.

A text search of Minn. R. ch. 6800 found no 'office use' provision. The Board's FAQ pages (mn.gov) could not be fetched to check for guidance.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Minn. Stat. §151.252, subd. 1a bars acting as an outsourcing facility without a Board of Pharmacy license (manufacturer-level fee). It requires proof of FDA registration under 21 U.S.C. §353b, proof of home-state licensure where that state requires it, and a separate license 'for each outsourcing facility located outside of the state at which drugs that are shipped into the state are prepared.' The Board may not issue or renew the license unless the facility passes a cGMP inspection by a Board representative. An out-of-state facility may instead submit an FDA or home-state cGMP inspection report from the prior 24 months to avoid paying for the Board's inspection. Licensed outsourcing facilities must also file annual reports of payments to Minnesota practitioners (subd. 3).

Board application details (mn.gov) could not be fetched. The license requirement itself is clear in statute.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Minnesota is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Minn. Stat. 152.12, subd. 1 authorizes a licensed MD/DO, APRN, certified midwife, PA and certain other licensees, in the course of professional practice only, to prescribe, administer and dispense Schedule II-V controlled substances. The only state Board of Pharmacy controlled-substance registration in that section is for persons doing research with controlled substances (subd. 3), and even that is waived for those complying with federal research rules. No practitioner CS registration is required.

Text read is the 2025 Minnesota Statutes edition (via WebFetch). Minnesota requires PMP registration for DEA-registered prescribers (not opened here).

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Minn. Stat. 152.126, subd. 6(d) requires, since January 1, 2021, a prescriber or delegate to access PMP data before issuing an initial prescription order for a Schedule II-IV opiate, and at least every three months for patients on opiates for chronic pain or in medication-assisted treatment for opioid addiction. Exceptions (subd. 6(e)) include palliative/hospice/end-of-life care, cancer pain, non-refillable supplies of 5 days or less, a provider-patient relationship longer than one year, prescriptions within 14 days after surgery (3 days after oral surgery), hospital inpatients, drugs administered by or in the presence of the prescriber or pharmacist, emergencies, and system failures. All DEA-registered prescribers must hold a PMP account (subd. 6(c)).

Testosterone (C-III, not an opiate) is not caught. Text read from the 2025 Minnesota Statutes (latest amendments 2024). PDMP TTAC also lists 245G.22, 256B.0638 and MR 5221.6110 (treatment-program, Medicaid opioid program and workers' comp provisions - not reviewed).

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Minn. Stat. 151.37, subd. 2 authorizes licensed practitioners to prescribe, administer and dispense legend drugs in the course of practice. A practitioner who dispenses oral legend drugs for profit (above acquisition cost, or cost plus compounding and packaging) must first file a statement with the licensing board; the statement is public. No separate dispensing permit is required.

Read from the 2025 Minnesota Statutes edition on the Revisor site. Answer is yes because only a for-profit statement (not a permit) is required.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

A physician licensed elsewhere may provide interstate telehealth to Minnesota patients after registering annually with the Board of Medical Practice (Minn. Stat. 147.032) and is held to Minnesota standards (147.033). Under Minn. Stat. 151.37, subd. 2(d)-(e), a prescription for Schedule II-IV controlled substances (152.02, subds. 3-5), muscle relaxants, butalbital products and opioid-acting analgesics is valid only if based on an in-person examination by the prescriber, another practitioner in the same group or clinic, or a consulting or referring practitioner. PDE5 inhibitors for erectile dysfunction and medications for opioid use disorder may instead rely on a telehealth examination. IMLC: member.

Exam rule read in the current Minnesota Statutes 151.37 on the Revisor site; registration details from CCHP.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Minnesota Board of Nursing's website was checked on 2026-09-23 for a position statement, advisory opinion or FAQ on cosmetic injectables (neuromodulators, fillers) and none was found. RN practice therefore falls under the state's general nurse practice act, which was not reviewed for this entry.

The Board of Nursing site lists general scope-of-practice and protocol guidance but no aesthetics-specific statement.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Minnesota Board of Nursing's website was checked on 2026-09-23 for guidance on IV hydration clinics (prior exams, standing orders, mobile services) and none was found.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies Minnesota as strict, citing Minn. Stat. ch. 319A, Granger v. Adson (1933) and Isles Wellness v. Progress N. Ins. Co. (2005); MedPath Compliance (reviewed 2026-06-20) also lists Minnesota as a CPOM state.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

No Minnesota statute, rule or board policy on delegation of cosmetic laser/IPL procedures or a laser-operator credential was located on 2026-09-23.

A vendor compilation reports that Minnesota allows advanced-practice estheticians with added training to perform laser hair removal; not verified.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Minnesota was not among them, but this research did not confirm its statutes. Minnesota's CLIA state agency is Minnesota Dept. of Health CLIA Program (health.clia@state.mn.us, 651-201-4200); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Minnesota's rule. Minnesota's lab regulator (CLIA state agency) is Minnesota Dept. of Health CLIA Program (health.clia@state.mn.us, 651-201-4200). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Minnesota is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Minn. Stat. §116.943 (Amara's Law) banned intentionally added PFAS in cosmetics and ten other product categories from Jan 1, 2025. Manufacturers of products with intentionally added PFAS must report to the MPCA (the statute sets Jan 1, 2026 and lets the commissioner extend the deadline). From Jan 1, 2032, all products with intentionally added PFAS are banned unless designated 'currently unavoidable', a designation not available to the 2025 categories. Minn. Stat. §325F.177 bans formaldehyde, and ingredients that release more than 0.05% formaldehyde, in children's products applied to the body of a child under 8 (manufacturers and wholesalers from Aug 1, 2014; retailers from Aug 1, 2015).

Final MPCA rules were approved Dec 8, 2025 (Morgan Lewis). Check MPCA for the current reporting deadline, which may have been extended. The statute page notes 2025 amendments. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.